/PRNewswire/ A Phase 2b clinical trial involving more than 150 children and adolescents with Tourette syndrome found ecopipam significantly reduced the.
Emalex Biosciences raised $250 million, a Series D round of funding that was the biggest biotech financing of the past week. Other biotech startup that raised money include Alterome Therapeutics, hC Bioscience, and Novadip Bioscience.